Belzutifan(Welireg) is a novel therapeutic drug for tumors associated with von Hippel-Lindau (VHL) syndrome. It inhibits the growth of tumor cells by targeting HIF-2α and is indicated for specific types of renal cell carcinoma, central nervous system hemangioblastoma, and pancreatic neuroendocrine tumors.

Dosage of Belzutifan

Proper dosage is key to confirming the efficacy of Belzutifan and can help reduce the occurrence of side effects.

Recommended dosage and administration

The recommended dose of Belzutifan is 120 mg orally once daily until disease progression or unacceptable toxicity. It is recommended to take it at the same time each day, with or without a meal. Swallow the tablets whole, do not chew, crush or split the tablets before swallowing. If a dose is missed, it can be retaken as soon as possible on the same day; If you vomit after taking it, you don't need to take it again and continue taking it as usual the next day.

Medication adjustment for special populations

For patients with mild to moderate hepatic or renal impairment, dose adjustment is usually not necessary. However, patients with dual UGT2B17 and CYP2C19 dysmetabolism need to be closely monitored for signs and symptoms, as these patients may experience higher levels of drug exposure.

Understanding and adhering to specific medication guidance for different patient populations can help improve the safety and effectiveness of treatment.

Precautions for the use of Belzutifan

While using Belzutifan, there are a few key things to keep in mind that can help improve the effectiveness of treatment while reducing unnecessary risks.

Drug interactions

Concomitant use with UGT2B17 or CYP2C19 inhibitors should be avoided, and concomitant use with sensitive CYP3A4 substrates and hormonal contraceptives should be avoided. These combinations may increase exposure to Belzutifan and thus lead to an increased risk of adverse effects.

Guidelines for the use of medications for special populations

Belzutifan should be avoided in pregnant and lactating women as it may cause serious adverse effects to the fetus or infant. In addition, men and women of childbearing potential should use effective contraception during treatment and for some time after discontinuation.

Formulating appropriate medication guidelines can maximize the maintenance of medication safety for special populations.

Healthy lifestyle of Belzutifan patients

In addition to proper use of Belzutifan, maintaining healthy daily habits is an important part of supportive care.

Dietary advice

A balanced diet is very important for patients treated with Belzutifan. Consuming enough protein, vitamins, and minerals can help boost the immune system and combat possible side effects such as anemia and fatigue. Avoid spicy, greasy and other irritating foods, and limit excessive intake of sugar and salt.

Exercise and rest

Proper physical activity is equally important with adequate rest. Regular physical activity can improve your mood and boost your stamina, while adequate sleep can help your body recover. Patients should choose the exercise method that suits them according to their own conditions and maintain good work and rest habits.

Combined with a healthy diet, moderate exercise, and adequate rest, patients can be fully supported to better cope with their illness.